Abstract
Duchenne muscular dystrophy (DMD) is an X-linked genetic disorder that causes progressive weakness and wasting of skeletal muscular and myocardium in boys due to mutation of dystrophin. The structural integrity of each individual skeletal and cardiac myocyte is significantly compromised upon physical stress due to the absence of dystrophin. The progressive destruction of systemic musculature and myocardium causes affected patients to develop multiple organ disabilities, including loss of ambulation, physical immobility, neuromuscular scoliosis, joint contracture, restrictive lung disease, obstructive sleep apnea, and cardiomyopathy. There are some central nervous system-related medical problems, as dystrophin is also expressed in the neuronal tissues. Although principal management is to mainly delay the pathological process, an enhanced understanding of underlying pathological processes has significantly improved quality of life and longevity for DMD patients. Future research in novel molecular approach is warranted to answer unanswered questions.
Similar content being viewed by others
References
Emery AE (1991) Population frequencies of inherited neuromuscular diseases – a world survey. Neuromuscul Disord 1:19–29
Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N (2014) A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord 24:482–491
Mercuri E, Muntoni F (2013) Muscular dystrophies. Lancet 381:845–860
Bushby K, Finkel R, Birnkrant DJ et al (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9:77–93
Strehle EM, Straub V (2015) Recent advances in the management of Duchenne muscular dystrophy. Arch dis child 100:1173–1177
Anderson JL, Head SI, Rae C, Morley JW (2002) Brain function in Duchenne muscular dystrophy. Brain 125(Pt 1):4–13
Snow WM, Anderson JE, Jakobson LS (2013) Neuropsychological and neurobehavioral functioning in Duchenne muscular dystrophy: a review. Neurosci Biobehav rev 37:743–752
Bushby K, Finkel R, Birnkrant DJ et al (2010) Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 9:177–189
Wein N, Alfano L, Flanigan KM (2015) Genetics and emerging treatments for Duchenne and Becker muscular dystrophy. Pediatr Clin North Am 62:723–742
Muntoni F, Torelli S, Ferlini A (2003) Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2:731–740
Ferlini A, Neri M, Gualandi F (2013) The medical genetics of dystrophinopathies: molecular genetic diagnosis and its impact on clinical practice. Neuromuscul Disord 23:4–14
Wallace GQ, McNally EM (2009) Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies. Annu Rev Physiol 71:37–57
Flanigan KM (2014) Duchenne and Becker muscular dystrophies. Neurol Clin 32:671–688
Brandsema JF, Darras BT (2015) Dystrophinopathies. Semin Neurol 35:369–384
Flanigan KM, Dunn DM, von Niederhausern A et al (2009) Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat 30:1657–1666
Tuffery-Giraud S, Beroud C, Leturcq F et al (2009) Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum Mutat 30:934–945
Melacini P, Fanin M, Danieli GA et al (1993) Cardiac involvement in Becker muscular dystrophy. J Am Coll Cardiol 22:1927–1934
Saito M, Kawai H, Akaike M, Adachi K, Nishida Y, Saito S (1996) Cardiac dysfunction with Becker muscular dystrophy. Am Heart J 132:642–647
Connuck DM, Sleeper LA, Colan SD et al (2008) Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J 155:998–1005
Finsterer J, Stollberger C (2008) Cardiac involvement in Becker muscular dystrophy. Can J Cardiol 24:786–792
Towbin JA, Hejtmancik JF, Brink P et al (1993) X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 87:1854–1865
Cohen N, Muntoni F (2004) Multiple pathogenetic mechanisms in X linked dilated cardiomyopathy. Heart 90:835–841
Diegoli M, Grasso M, Favalli V et al (2011) Diagnostic work-up and risk stratification in X-linked dilated cardiomyopathies caused by dystrophin defects. J Am Coll Cardiol 58:925–934
Schram G, Fournier A, Leduc H et al (2013) All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. J Am Coll Cardiol 61:948–954
Buyse GM, Goemans N, van den Hauwe M, Meier T (2013) Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy. Pediatr Pulmonol 48:912–920
Tandon A, Villa CR, Hor KN et al (2015) Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy. J Am Heart Assoc. doi:10.1161/JAHA.114.001338
Fenichel GM, Florence JM, Pestronk A et al (1991) Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 41:1874–1877
Shapiro F, Sethna N, Colan S, Wohl ME, Specht L (1992) Spinal fusion in Duchenne muscular dystrophy: a multidisciplinary approach. Muscle Nerve 15:604–614
McDonald DG, Kinali M, Gallagher AC, Mercuri E, Muntoni F, Roper H, Jardine P, Jones DH, Pike MG (2002) Fracture prevalence in Duchenne muscular dystrophy. Dev med child Neurol 44:695–698
Benditt JO, Boitano L (2005) Respiratory support of individuals with Duchenne muscular dystrophy: toward a standard of care. Phys Med Rehabil Clin N Am 16(1125–1139):xii
LoMauro A, D'Angelo MG, Aliverti A (2015) Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options. Ther Clin Risk Manag 11:1475–1488
Kurz LT, Mubarak SJ, Schultz P, Park SM, Leach J (1983) Correlation of scoliosis and pulmonary function in Duchenne muscular dystrophy. J Pediatr Orthop 3:347–353
Szeinberg A, Tabachnik E, Rashed N et al (1988) Cough capacity in patients with muscular dystrophy. Chest 94:1232–1235
Bach JR, Ishikawa Y, Kim H (1997) Prevention of pulmonary morbidity for patients with Duchenne muscular dystrophy. Chest 112:1024–1028
Polat M, Sakinci O, Ersoy B, Sezer RG, Yilmaz H (2012) Assessment of sleep-related breathing disorders in patients with duchenne muscular dystrophy. J Clin Med Res 4:332–337
Nozoe KT, Moreira GA, Tolino JR, Pradella-Hallinan M, Tufik S, Andersen ML (2015) The sleep characteristics in symptomatic patients with Duchenne muscular dystrophy. Sleep Breath 19:1051–1056
Amin RS, Kimball TR, Bean JA et al (2002) Left ventricular hypertrophy and abnormal ventricular geometry in children and adolescents with obstructive sleep apnea. Am J Respir Crit Care Med 165:1395–1399
Chan JY, Li AM, Au CT et al (2009) Cardiac remodelling and dysfunction in children with obstructive sleep apnoea: a community based study. Thorax 64:233–239
McNally EM, Kaltman JR, Benson DW et al (2015) Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, lung, and blood institute in collaboration with parent project muscular dystrophy. Circulation 131:1590–1598
McNally EM (2007) New approaches in the therapy of cardiomyopathy in muscular dystrophy. Annu Rev Med 58:75–88
Kamdar F, Garry DJ (2016) Dystrophin-deficient cardiomyopathy. J Am Coll Cardiol 67:2533–2546
Desguerre I, Christov C, Mayer M et al (2009) Clinical heterogeneity of duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up. PLoS One 4:e4347
Matsuoka S, Ii K, Akita H et al (1987) Clinical features and cardiopulmonary function of patients with atrophic heart in Duchenne muscular dystrophy. Jpn Heart J 28:687–694
Lee TH, Eun LY, Choi JY et al (2014) Myocardial atrophy in children with mitochondrial disease and Duchenne muscular dystrophy. Korean J Pediatr 57:232–239
Spurney CF (2011) Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions. Muscle Nerve 44:8–19
Thomas TO, Morgan TM, Burnette WB, Markham LW (2012) Correlation of heart rate and cardiac dysfunction in Duchenne muscular dystrophy. Pediatr Cardiol 33:1175–1179
Lanza GA, Dello Russo A, Giglio V et al (2001) Impairment of cardiac autonomic function in patients with Duchenne muscular dystrophy: relationship to myocardial and respiratory function. Am Heart J 141:808–812
Hor KN, Taylor MD, Al-Khalidi HR et al (2013) Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: effect of age and left ventricular systolic function. J Cardiovasc Magn Reson 15:107
Jefferies JL, Eidem BW, Belmont JW et al (2005) Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 112:2799–2804
Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Becane HM (2005) Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 45:855–857
Silva MC, Magalhaes TA, Meira ZM et al (2016) Myocardial fibrosis progression in Duchenne and Becker muscular dystrophy: a randomized clinical trial. JAMA Cardiol 2:190–199. doi:10.1001/jamacardio.2016.4801
Markham LW, Kinnett K, Wong BL, Woodrow Benson D, Cripe LH (2008) Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord 18:365–370
Barber BJ, Andrews JG, Lu Z et al (2013) Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy. J Pediatr 163:1080–1084.e1
Ahn AH, Kunkel LM (1993) The structural and functional diversity of dystrophin. Nat Genet 3:283–291
Hendriksen RG, Hoogland G, Schipper S, Hendriksen JG, Vles JS, Aalbers MW (2015) A possible role of dystrophin in neuronal excitability: a review of the current literature. Neurosci Biobehav Rev 51:255–262
Pane M, Messina S, Bruno C et al (2013) Duchenne muscular dystrophy and epilepsy. Neuromuscul Disord 23:313–315
Lindsay S, McAdam L, Mahendiran T (2017) Enablers and barriers of men with Duchenne muscular dystrophy transitioning from an adult clinic within a pediatric hospital. Disabil Health J 10:73–79
Yamaguchi M, Suzuki M (2015) Becoming a back-up carer: parenting sons with Duchenne muscular dystrophy transitioning into adulthood. Neuromuscul Disord 25:85–93
Schrans DG, Abbott D, Peay HL et al (2013) Transition in Duchenne muscular dystrophy: an expert meeting report and description of transition needs in an emergent patient population: (parent project muscular dystrophy transition expert meeting 17–18 June 2011, Amsterdam, The Netherlands). Neuromuscul Disord 23:283–286
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Tsuda, T. (2018). Clinical Manifestations and Overall Management Strategies for Duchenne Muscular Dystrophy. In: Bernardini, C. (eds) Duchenne Muscular Dystrophy. Methods in Molecular Biology, vol 1687. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7374-3_2
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7374-3_2
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7373-6
Online ISBN: 978-1-4939-7374-3
eBook Packages: Springer Protocols